dimethyl fumarate mylan
mylan ireland limited - dimetyylifumaraatti - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetyylifumaraatti - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetyylifumaraatti - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
ocutifex 0.25 mg/ml silmätipat, liuos, kerta-annospakkaus
pharma stulln gmbh - ketotifen hydrogen fumarate - silmätipat, liuos, kerta-annospakkaus - 0.25 mg/ml - ketotifeeni
zaditen 0.25 mg/ml silmätipat, liuos, kerta-annospakkaus
laboratoires thea - ketotifen fumarate - silmätipat, liuos, kerta-annospakkaus - 0.25 mg/ml - ketotifeeni
zaditen 0.25 mg/ml silmätipat, liuos
laboratoires thea - ketotifen fumarate - silmätipat, liuos - 0.25 mg/ml - ketotifeeni
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
maratoopi 15 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - topiramatum - tabletti, kalvopäällysteinen - 15 mg - topiramaatti